ADDICTOLYON
Services Hospitalo-Universitaires d'Addictologie de Lyon
PRINCIPALES PUBLICATIONS SCIENTIFIQUES DEPUIS 2020
de Ternay J, Larrieu A, Sauvestre L, Montègue S, Guénin M, Icard C, Rolland B. Insufficient physical activity is a global marker of severity in alcohol use disorder: results from a cross-sectional study in 382 treatment-seeking patients. Nutrients. 2022; 14(23), 4958; doi.org/10.3390/nu14234958
IF 6.7
Bolstad I, Toft H, Lien L, Moe JS, Rolland B, Bramness JG. Longitudinal determinants of insomnia among patients with alcohol use disorder. Alcohol. 2022; S0741-8329(22)00116-1. doi: 10.1016/j.alcohol.2022.11.002.
IF 2.6
Fiorito AM, Aleman A, Blasi G, Bourque J, Cao H, [...], Venkatasubramanian G, Villarreal M, Wang Y, Wolf DH, Yun JY, Fakra E, Sescousse G. Are Brain Responses to Emotion a Reliable Endophenotype of Schizophrenia? An Image-Based Functional Magnetic Resonance Imaging Meta-analysis. Biol Psychiatry. 2022; S0006-3223(22)01357-9. doi: 10.1016/j.biopsych.2022.06.013
IF 12.8
Hultman C, Vadlin S, Rehn M, Sescousse G, Nilsson KW, Åslund C. Autonomic responses during Gambling: the Effect of Outcome Type and Sex in a large community sample of young adults. J Gambl Stud. 2022. doi: 10.1007/s10899-022-10118-6.
IF 3.4
Rolland B, Dalon F, Gauthier N, Nourredine M, Bérard M, Carton L, Brousse G, Llorca PM, Jacoud F, Van Ganse E, Belhassen M. Antipsychotic prescribing practices in real-life (APPREAL study): Findings from the French National Healthcare System Database (2007–2017). Front Psychiatry. 2022; doi.org/10.3389/fpsyt.2022.1021780
IF 5.4
de Beaurepaire R, Rolland B. Baclofen in alcohol use disorder: An analysis of the data provided by the French "Temporary Recommendation for Use" 2014-2017 cohort.
Front Psychiatry. 2022; 13:949750.
IF 5.4
Argote M, Sescousse G, Brunelin J, Fakra E, Nourredine M, Rolland B. Association between formal thought disorder and cannabis use: a systematic review and meta-analysis
Schizophrenia (Heidelb). 2022; 8(1):78. doi: 10.1038/s41537-022-00286-0.
IF 5.0
Rolland B, Lions C, Di Beo V, Carrieri P, Authier N, Barré T, Delorme J, Mathurin P, Bailly F, Protopopescu C, Marcellin F. Adherence to opioid agonist therapy predicts uptake of direct-acting antivirals in people who use drugs: results from the French national healthcare database (the ANRS FANTASIO study). Harm Reduct J. 2022; 19(1):119. doi: 10.1186/s12954-022-00702-9.
IF 4.8
Fovet T, Wathelet M, Benbouriche M, Benradia I, Roelandt JL, Thomas P, d'Hondt F, Rolland B. Substance Use, Substance Use Disorders, and Co-Occurring Psychiatric Disorders in Recently Incarcerated Men: A Comparison with the General Population. Eur Addict Res. 2022; 28(5):368-376. doi: 10.1159/000526079.
IF 4.0
Lespine LF, Bramness JG, Pignon B, Vaiva G, Thomas P, Roelandt JL, Benradia I, Amad A, Geoffroy PA, Rolland B. Gender-related Associations between Psychiatric Disorders and Alcohol Use Disorder: Findings from The French "Mental Health in the General Population" Survey. Arch Womens Ment Health. 2022; 25(5):895-902. doi: 10.1007/s00737-022-01253-5.
IF 4.4
Carton L, Icick R, Weibel S, Dematteis M, Kammerer E, Batisse A, Rolland B; French coordination for adult ADHD. What is the potential for abuse of lisdexamfetamine in adults? A preclinical and clinical literature review and expert opinion. Expert Rev Clin Pharmacol 2022; 15(8):921-925. doi: 10.1080/17512433.2022.2112950.
IF 4.1
Louvet A, Trabut JB, Moreno C, Moirand R, Aubin HJ, Ntandja Wandji LC, Nourredine M, Ningarhari M, Ganne-Carrié N, Pageaux GP, Bailly F, [...], Mathurin P, Rolland B; for the Groupe collaboratif AFEF-SFA Maladie du foie liée à l'alcool. Management of alcohol-related liver disease: the French Association for the Study of the Liver and the French Alcohol Society clinical guidelines. Liver Int. 2022; 42(6):1330-1343. doi: 10.1111/liv.15221.
IF 8.7
de Ternay J, Leblanc P, Michel P, Benyamina A, Naassila M, Rolland B. One-month alcohol abstinence national campaigns: a scoping review of the harm reduction benefits. Harm Reduct J. 2022; 19(1):24. doi: 10.1186/s12954-022-00603-x
IF 4.8
Chappuy M, Fezzani L, Ragonnet D, Berger A, Duvernay N, Lack P, Rolland B. Proportion and conditions of use of intranasal take-home naloxone kits: A retrospective study in two French outpatient addiction centers, 2016-2020. Therapies. 2022; 77(5):581-584. doi: 10.1016/j.therap.2022.01.006.
IF 3.4
Guiraud J, Addolorato G, Antonelli M, Aubin HJ, [...], Rolland B, Rotondo C, Scherrer B, Simon N, Skala K, Söderpalm B, Somaini L, Sommer WH, Spanagel R, Vassallo GA, Walter H, van den Brink W. Sodium oxybate for the maintenance of abstinence in alcohol-dependent patients: An international, multicenter, randomized, double-blind, placebo-controlled trial.
J Psychopharmacol. 2022; 36(10):1136-1145. doi: 10.1177/02698811221104063.
IF 4.2
Chappuy M, Nourredine M, Clerc B, Fahmi M, Misslin P, Berthier M, Laloi L, Rolland B. Gabapentinoid use in French most precarious populations: Insight from Lyon Permanent Access to Healthcare (PASS) units, 2016-1Q2021. Fundam Clin Pharmacol. 2022; 36(2):448-452. doi: 10.1111/fcp.12726.
IF 2.7
Catoire S, Nourredine M, Lefebvre S, Couraud S, Gronfier C, Rey R, Peter-Derex L, Geoffroy PA, Rolland B. Tobacco-induced sleep disturbances: A systematic review and meta-analysis. Sleep Med Rev. 2021; 60:101544. doi: 10.1016/j.smrv.2021.101544.
IF 11.4
Chapron SA, Nourredine M, Dondé C, Haesebaert F, Micoulaud-Franchi JA, Geoffroy PA, Rolland B. Efficacy and safety of topiramate for reducing impulsivity: A transdiagnostic systematic review and meta-analysis of a common clinical use. Fundam Clin Pharmacol. 2021; 36(1):4-15. doi: 10.1111/fcp.12710.
IF 2.7
Chappuy M, Meroueh F, Trojak B, Bachellier J, Bendimerad P, Kosim M, Hjelmström P, Nubukpo P, Brousse G, Rolland B. Factors of Interest in Extended-Release Buprenorphine: Comparisons Between Incarcerated and Non-Incarcerated Patients with Opioid Use Disorder.
Patient Prefer Adherence. 2021; 15:1259-1267. doi: 10.2147/PPA.S311674.
IF 2.1
Luquiens A, Berger-Viergat A, Larrieu A, Artigaud L, Fener C, Adamson S, Laprévote V, Rolland B. Validation of the French version of the Cannabis Use Disorder Identification Test-Revised and comparison with the Cannabis Abuse Screening Test for screening cannabis use disorder in a psychiatric sample.
Drug Alcohol Rev. 2021; 40(7):1334-1339. doi: 10.1111/dar.13298.
IF 4.0
Laconi S, Palma-Alvarez RF, Stöver H, Padberg C, Jamin D, Meroueh F, Chappuy M, Roncero C, Rolland B. Validation of the Opioid Overdose Knowledge (OOKS) and Attitudes (OOAS) Scales in French, Spanish, and German Languages, among a Sample of Opioid Users.
Eur Addict Res. 2021; 27(5):326-331. doi: 10.1159/000511770.
IF 4.0
Rolland B, Trojak B, Nourredine M, Bachellier J, Chappuy M, Bendimerad P, Kosim M, Hjelmström P, Meroueh F, Nubukpo P, Brousse G. Determinants of interest in extended-released buprenorphine: A survey among 366 French patients treated with buprenorphine or methadone. Drug Alcohol Depend. 2021; 220:108492. doi: 10.1016/j.drugalcdep.2020.108492.
IF 4.9
Nourredine M, Gering A, Fourneret P, Rolland B, Falissard B, Cucherat M, Geoffray MM, Jurek L. Association of Attention-Deficit/Hyperactivity Disorder in Childhood and Adolescence With the Risk of Subsequent Psychotic Disorder: A Systematic Review and Meta-analysis
JAMA Psychiatry. 2021; 78(5):519-529. doi: 10.1001/jamapsychiatry.2020.4799.
IF 26.9
Bertin C, Delage N, Rolland B, Pennel L, Fatseas M, Trouvin AP, Delorme J, Chenaf C, Authier N. Analgesic opioid use disorder in patients with chronic non-cancer pain: A holistic approach for tailored management. Neurosci Biobehav Rev. 2021; 121:160-174.
doi.org/10.1016/j.neubiorev.2020.12.015
IF 9.1
Dobre D, Schwan R, Jansen C, Schwitzer T, Martin O, Ligier F, Rolland B, [...], Leboyer M, Thomas P, Gorwood P, Laprevote V. Clinical features and outcomes of COVID-19 patients hospitalized for psychiatric disorders: a French multi-centered prospective observational study Psychol Med. 2021; 1-9. doi: 10.1017/S0033291721001537.
IF 7.7
Rolland B, Haesebaert F, Zante E, Benyamina A, Haesebaert J, Franck N. Global Changes and Factors of Increase in Caloric/Salty Food Intake, Screen Use, and Substance Use During the Early COVID-19 Containment Phase in the General Population in France: Survey Study. JMIR Public Health Surveill. 2020; 6(3):e19630. doi: 10.2196/19630.
IF 14.6
Chappuy M, Trojak B, Nubukpo P, Bachellier J, Bendimerad P, Brousse G, Rolland B. Prolonged-release buprenorphine formulations: Perspectives for clinical practice. Therapies. 2020; 75(5):397-406. doi: 10.1016/j.therap.2020.05.007.
IF 3.4
Geoffroy PA, Lejoyeux M, Rolland B. Management of insomnia in alcohol use disorder. Expert Opin Pharmacother. 2020; 21(3):297-306. doi: 10.1080/14656566.2019.1705279.
IF 4.1
Chappuy M, Boulanger A, Nourredine M, Fourneret P, Rolland B. Disparate regulatory status of methylphenidate for adults with ADHD across Europe. Lancet Psychiatry. 2020; 7(1):e1-e2. doi: 10.1016/S2215-0366(19)30482-1.
IF 27.1
Meyrel M, Rolland B, Geoffroy PA. Management of insomnia in alcohol use disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2020; 99:109831. doi: 10.1016/j.pnpbp.2019.109831.
IF 4.6
Rolland B, Simon N, Franchitto N, Aubin HJ. France Grants an Approval to Baclofen for Alcohol Dependence. Alcohol Alcohol. 2020; 55(1):44-45. doi: 10.1093/alcalc/agz082.
IF 3.9
Barré T, Marcellin F, Di Beo V, Delorme J, Rojas Rojas T, Mathurin P, Protopopescu C, Bailly F, Coste M, Authier N, Carrieri MP, Rolland B. Untreated alcohol use disorder in people who inject drugs (PWID) in France: a major barrier to HCV treatment uptake (the ANRS-FANTASIO study). Addiction. 2020; 115(3):573-582. doi: 10.1111/add.14820.
IF 7.2
Pignon B, Sescousse G, Amad A, Benradia I, Vaiva G, Thomas P, Geoffroy PA, Roelandt JL, Rolland B. Alcohol Use Disorder Is Differently Associated With Psychotic Symptoms According To Underlying Psychiatric Disorders: A General Population Study. Alcohol Alcohol. 2020; 55(1):112-120